News

Linda Laskowski-Jones, MS, APRN, ACNS-BC, CEN, NEA-BC, FAAN, discusses how oncology nurse leaders can help improve working environments for their staff.

A multidisciplinary intervention to address financial toxicity led to improved overall survival rates for patients with blood cancers.

Holistic options like acupuncture and music therapy may benefit those undergoing cancer treatment.

An analysis of patient-reported outcomes showed that patients with advanced ovarian cancer experienced fewer abdominal or gastrointestinal toxicities with mirvetuximab soravtansine than with chemotherapy.

The more chronic conditions patients have, the more likely they are to be in debt.

Selpercatinib demonstrated a promising efficacy profile in patients with RET-fusion positive solid tumors.

Phase 2 findings indicate that a combination of avelumab and axitinib may draw promising responses in patients with advanced type B3 thymoma and thymic carcinoma.

A subgroup of the phase 3 GLOW trial revealed a unique relationship between undetectable minimal residual disease status and progression-free survival in elderly or unfit patients with chronic lymphocytic leukemia who received ibrutinib plus venetoclax.

Following promising efficacy data from the phase 3 TROPiCS-02 trial, the FDA has granted sacituzumab govitecan priority review status on the indication of HR+/HER2 metastatic breast cancer.

Dana-Farber Cancer Institute, one of the world’s leading cancer research and treatment centers, has partnered with the Parker Institute for Cancer Immunotherapy, the leading network of immuno-oncology expertise in the world, as a member of the PICI Network with a goal to better understand the tumor microenvironment across cancer types and translate these basic discoveries to the clinic as impactful cancer immunotherapies.

Sophia George, PhD, is hoping to find new strategies for early detection of ovarian cancer, a disease that is particularly deadly for African American, Caribbean, and Jewish women.

Sylvester Comprehensive Cancer Center researchers Lluis Morey, PhD, and Ramiro Verdun, PhD, have received a $1.8 million NIH R01 grant to study the epigenetic mechanisms that drive head and neck cancers.

Researchers are investigating ways to make immunotherapies more effective.

Individuals with AML who underwent a bone marrow transplant are at an increased risk of developing subsequent neoplasms, and other chronic health conditions.

At the 2022 ASCO Quality Care Symposium, researchers discussed how Medicaid expansion was tied to earlier diagnoses, more accessible palliative care, and decreased mortality rates for patients with cancer.

Advanced practice providers are the future of survivorship care because of the tremendous value they offer to the practice and its patients.

Tivozanib, an oral VEGF inhibitor, improved overall survival in patients with relapsed or refractory, advanced renal cell carcinoma.

A combination of the aromatase inhibitor letrozole and the CDK4/6 inhibitor abemaciclib may help patients with recurrent estrogen receptor–positive endometrial cancer achieve responses.

Optimal treatment sequencing for patients with BRAF-mutated melanoma involves frontline immunotherapy following by BRAF/MEK inhibition, according to investigators.

At the 2022 ASCO Quality Care Symposium, an adverse event analysis showed that abemaciclib has a manageable safety profile and that dose reductions may be a key aspect of appropriate symptom management.

Neoadjuvant chemotherapy allowed 79% of patients with early-stage I/IIA rectal cancer to pursue organ-sparing excision surgery, potentially preserving their quality of life and bowel function.

Neratinib was associated with a clinical benefit rate of 45.5% among patients with metastatic or recurrent HER2-mutated cervical cancer.

Structured preceptorships promote competence, confidence, and job satisfaction in new oncology nurse practitioners.

Following treatment with rusfertide, patients with polycythemia vera were able to significantly reduce their need for blood draws.

Derazantinib, an FGFR inhibitor, was associated with a median progression-free survival (PFS) of 7.8 months in patients with FGFR2-positive intrahepatic cholangiocarcinoma.

The median radiographic progression-free survival (rPFS) was 11.2 months among patients with castration-resistant prostate cancer who received rucaparib. In the control arm, median rPFS was 6.4 months.

Anne Delengowski, RN, MSN, AOCN, CCCTM, discusses the evolving role of the oncology nurse in clinical trial research.

Elacestrant, an oral selective estrogen receptor degrader, may hold the potential to replace intramuscular fulvestrant injections for patients with endocrine receptor–positive, HER2-negative breast cancer.

Menstrual suppression can improve outcomes and quality of life in premenopausal women undergoing hematopoietic stem cell transplant.

By certain accounts, the breast cancer awareness ribbon was actually peach before it was pink.